Monday, 20 February 2012

George Pantziarka TP53 Trust On Facebook

As part of our strategy to make contact with as many people as possible with Li Fraumeni Syndrome and other TP53-related conditions, we have just created a George Pantziarka TP53 Trust presence on Facebook. As well as a Facebook page here: http://www.facebook.com/pages/The-George-Pantziarka-TP53-Trust/339541346091212, there is also a group here: http://www.facebook.com/groups/117336885058553/

If you're on Facebook please drop by. If you know of anyone with a TP53-related condition, or an interest in TP53, then please pass on the word.

Monday, 13 February 2012

Interview With Galina Selivanova

Professor Galina Selivanova (GS) heads a research group in the Department of Microbiology, Tumor and Cell Biology of the Karolinska Institute in Stockholm, one of Europe's leading medical schools and research institutes. Her work focuses on re-activating TP53 using small molecule drugs, some of which are beginning to emerge into clinical trials. She is generally acknowledged to be one of the world's leading researchers on TP53 as a medical target in oncology. She is interviewed here: http://www.tp53.co.uk/index.php/interview-galina-selivanova and what she has to say is generally optimistic, which is welcome given how optimism is in precious short supply when it comes to Li Fraumeni Syndrome

Friday, 10 February 2012

Oncology Nurses Society On LFS

General information on Li Fraumeni Syndrome is comparatively rare, which is frustrating when you're trying to explain what it is to a doctor, nurse or other medical profession, let alone family and friends. However, the journal ONS Connect, published by the Oncology Nursing Society, have published a five-minute introduction to Li Fraumeni Syndrome.

Obviously aimed at the oncology nurse, it covers a reasonable level of detail and describes the current state of the art when it comes to the condition. If you need to point your nurse or doctor to a source that they can trust, then point them at this article:

http://www.onsconnect.org/2011/03/5min/an-introduction-to-li-fraumeni-syndrome

And of course, point them to http://www.tp53.co.uk as well...

Monday, 6 February 2012

Omega 3s, Stress and Cancer

Stress is a fact of life for cancer sufferers not just when they are undergoing treatment, but beyond that too, once they are in remission. It’s a fact life for people with Li Fraumeni Syndrome and other TP53-related conditions, and for those with Lynch Syndrome or other inherited conditions that predispose to cancer. This would be bad enough if we didn’t also know that stress can negatively affect the health, including negatively affecting the immune system. And, to cap it all, this knowledge itself causes stress, thereby creating one of those horrible vicious cycles that can lead to depression and anxiety.

Before reaching for the anti-depressants though, there are some positive things that can be done to tackle this stress. And, as a bonus, many of these steps to tackle stress can also boost the immune system and generally have a positive effect on health. What’s more, there is also accumulating evidence that many of the steps that I will outline are also good for people in the middle of cancer treatment, not just those who are in remission or worried about the next test results.

These positive steps include:

  • Exercise
  • Meditation
  • Tackling sleep problems
  • Improving diet
  • Omega 3 fatty acids


Tuesday, 31 January 2012

Bisphosphonates and side effects

It's generally accepted that bone tumours - whether from primary tumours like osteosarcoma or from metastatic disease - are hard to deal with. Bone cancer pain is difficult to control, and bone tumours can cause fractures and other significant problems, so finding a way of controlling these tumours is essential. To this end there is a whole class of drugs called bisphophonates which are emerging into general oncological practice. These drugs have been found to be effective in slowing the spread of bone tumours, and in helping deal with the pain that they induce. In terms of primary bone cancers, a number of trials are on-going in which these bisphophonate drugs are being used alongside the standard treatments for osteosarcoma. And, as an added bonus, there is evidence that the newer bisphosphonates such as zoledronate and ibandronate, have direct anti-tumour and immune-boosting effects too.

However, there is a big risk that comes with these drugs, which originated as treatments for osteoporosis, and that is a condition called osteonecrosis of the jaw (ONJ). This condition, which occurs in a small subset of patients can cause severe lesions in the jaw, and which can, in a very few cases lead to the crumbling of the jaw. To date there has been no way of knowing which patients are likely to get ONJ, which is a worry for patients taking them, and of course a concern for doctors who prescribe them.

But there may be some good news on the way. Researchers at the Columbia University College of Dental Medicine have done an analysis of patients who developed ONJ, looking at whether or not there is a genetic component to it. And it does appear that this is the case, with variations in a gene called RBMS3 being associated with the occurence of ONJ. This means that in time a genetic test will become available which will help doctors predict which patients are more or less likely to develop ONJ. If it means that doctors will become more confident in prescribing bisphosphonates to cancer patients who need it, then that's really good news.

For more details see the paper here: http://www.ncbi.nlm.nih.gov/pubmed/22267851.

Monday, 30 January 2012

Li Fraumeni Syndrome - New Surveillance Protocol

Many people who have Li Fraumeni Syndrome (LFS) or other TP53 abnormality are often diagnosed when they are suffering cancer - sometimes for the second or third time, as happened with our son George. They are in the thick of cancer treatment and are focused on the immediate problems at hand. However, for people who are not suffering from cancer, a diagnosis of LFS or other TP53 abnormality is likely to be a huge shock. All of a sudden the future becomes uncertain and frightening. The stress is immense.

The answer to the obvious question of 'what happens now?', is most often a variation on 'wait and see'. Currently, in the UK at least, the key thing is to put in place a system in which any LFS patient gets high priority should symptoms crop up. No waiting around for appointments for investigations, no hanging around while one doctor after another mulls things over.

However, a team of doctors in Canada and the United States have trialled a more active program of clinical surveillance. This program consists of regular blood tests and scans, trying to catch things before they become symptomatic. This is a major step forward for LFS patients.

I have written about it on the George Pantziarka TP53 Trust website here: http://www.tp53.co.uk/index.php/lfs-surveillance-protocol

It's required reading for anyone interested in TP53 and Li Fraumeni Syndrome. If you are a sufferer it's something you really need to know about, and, just as importantly, it's something that your doctors need to know about too.

Wednesday, 18 January 2012

No To The US Research Works Act

Access to information is essential to patients and doctors researching different medical conditions, including cancer. Journal papers offer the latest thinking on disease progression, reports of investigations in fundamental biology, new drugs, clinical trial results and so on. For those with chronic or life-threatening conditions, medical research offers the hope of new insights, new treatments and greater understanding. And, as I’ve written before on this site, access to medical research should be free to all, especially for the research that we – as citizens – have paid for through our taxes.

However, free and open access, as enshrined in the policies of the National Institutes of Health in the United States, conflicts with the commercial interests of the journal publishers. These companies make a lot of money by publishing scientific journal. The subscription fees for journals run into the thousands of dollars a year – way beyond what we as patients and their carers can afford. But the journals make money because university and medical school libraries, private companies and so on subscribe to them. An increased move to open access threatens this source of income.

So, the journals are fighting back and in the US there is now a Research Works Act being considered. This would basically take the publicly funded research results that are published by the NIH and open access journals back behind a paywall. No more free access to the latest information. If you want a particular paper you’ll either have to gain access to a university library or else pay the fees to access the paper (and fees range upwards of $30 per article).

If this Act goes ahead it will be a real loss. It will also be a grave injustice. For tax payers it will mean they are paying twice – once for the research to be carried out, and again should they want to read the results for themselves. But it will also mean denying access to potentially life-saving research to cancer patients at a time when they need it the most.

This site gets a lot of traffic from the United States. Please, if you are a US citizen please act now to stop the Research Works Act from becoming law. Write to your representative, write to your local newspaper, and if you are a scientist or doctor then please write to your professional association or society to take a stand in defence of patient rights.